KFAR MALAL, Israel, October 29, 2018 /PRNewswire/ --
Medial EarlySign (earlysign.com),
These new hires highlight Medial EarlySign's success in implementing its machine learning solutions within healthcare organizations as well as its commitment to ensuring organizations receive the highest quality insights to assist them in improving patients' health, provide proactive care and aid in effective resource allocation.
"Medial EarlySign's proprietary machine-learning based technology is increasingly sought after in the U.S. and around the world, and we welcome Patrick and Brandon to help us meet the growing demand for our solutions," said Ori Geva, CEO and Co-founder of Medial EarlySign. "We are confident and excited for both hires to further our continued expansion and success of implementing our AI-based, patient-specific treatment prioritization platforms for lower GI disorders, diabetes and other life-threatening conditions."
Wells brings over 18 years of experience in managing complex solutions and delivering strategic programs to provide clients with actionable insights that improve healthcare initiatives. Most recently, he served as Vice President of Advisory Services at IBM Watson Health and Deloitte & Touche, where he was instrumental in leading multiple complex client engagements. He also held leadership roles at Axentis (acquired by Wolters Kluwer) and Per-Se Technologies (acquired by McKesson) where he managed strategic client relationships.
"Medial EarlySign has emerged as a key player in health AI and predictive analytics, and is one of the few companies whose algorithms have been validated in clinical practice and analyzed in multiple peer-reviewed studies," said Wells. "I am excited to join Medial's team and culture. I was impressed with a culture focused on excellence and bringing healthcare organizations practical, easy to implement solutions with the potential to impact millions of lives."
Wilcher joins EarlySign from Wolters Kluwer Health, where he was the top sales producer in the Clinical Effectiveness business unit. Prior to that, he served as a Senior Director for Merritt Hawkins, a division of AMN Healthcare (NYSE: AMN), and handled business development efforts at Skylight Healthcare Systems, a fully-integrated patient engagement and education solution.
"Predictive analytics will provide an invaluable tool in improving care delivery through the early identification of high-risk patients," said Wilcher. "I am delighted to join Medial EarlySign and assist in spreading its powerful AI solutions to healthcare organizations and their physicians across the United States."
About Medial EarlySign
Medial EarlySign's advanced AI-based algorithm platform helps healthcare organizations accurately stratify populations to optimize care for individuals and prevent or delay serious health conditions, by leveraging routine blood test results, and common labs and EHR data. The company creates actionable opportunities for better clinical decision making and early intervention to improve patient outcomes, focus financial resources, and reduce overall costs. Medial EarlySign is developing a suite of AlgoMarker stratification models to address a variety of illnesses including cancers, diabetes and associated complications and other life-threatening conditions. The company's platform has been supported by peer-reviewed research published by internationally recognized health organizations and hospitals. Founded in 2009, Medial EarlySign is headquartered in Kfar Malal, Israel with a U.S. office in Newton, Massachusetts. For more information, please visit http://earlysign.com/.
Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign
Media Relations Contact: Ellie Hanson Finn Partners +929-222-8006 firstname.lastname@example.org
SOURCE Medial EarlySign
Subscribe to our Free Newsletters!